| 'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).BJU Int | PMID 34273231PMC9291594 | 2022-May | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.Clin Exp Rheumatol | PMID 34494957无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients.J Palliat Med | PMID 34704841PMC9080991 | 2022-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.AIDS Behav | PMID 34727272PMC9007827 | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial.Clin Lung Cancer | PMID 34810130无 PMCID | 2022-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects.Clin Pharmacokinet | PMID 34961905无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis.Eur Radiol | PMID 34978580PMC9038813 | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.Diabetes Obes Metab | PMID 34984815PMC9302620 | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).Gastric Cancer | PMID 34997449PMC9013328 | 2022-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.J Allergy Clin Immunol | PMID 35007624无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study.Hypertens Res | PMID 35058583PMC9010294 | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER).J Allergy Clin Immunol | PMID 35094848无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Re: Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial.Eur Urol | PMID 35105476无 PMCID | 2022-May | 0.45 | The record is identified as a randomized, Phase III oncology trial (FLAME trial) in humans, but the provided abstract is empty and no outcome data (survival, progression, etc.) are described in the metadata to confirm eligibility for KM digitization. The title indicates it is a 'Results' article, but the absence of an abstract or outcome signal prevents definitive inclusion. | 待处理 |
| First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.Ann Oncol | PMID 35124183无 PMCID | 2022-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.Ann Oncol | PMID 35131452无 PMCID | 2022-May | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling.Adv Clin Exp Med | PMID 35148573无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6.Epilepsia | PMID 35175622PMC9314914 | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.Neurol Neuroimmunol Neuroinflamm | PMID 35190477PMC9005047 | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of S-flurbiprofen plaster in knee osteoarthritis patients: A 2-week randomized controlled Phase III clinical trial compared to diclofenac gel.Int J Rheum Dis | PMID 35199483PMC9303700 | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma.Cancer Sci | PMID 35218673PMC9128191 | 2022-May | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer.Radiother Oncol | PMID 35259416无 PMCID | 2022-May | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Infect Dis | PMID 35286843PMC8916779 | 2022-May | 0.95 | The study is a randomized, phase 3 trial with a time-to-event primary endpoint (time to clinical improvement) and a drug intervention (CD24Fc). However, it investigates COVID-19, not a human malignant neoplasm, and is therefore excluded as non-oncology. | 待处理 |
| Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes Endocrinol | PMID 35298917无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Correlation of LH level and steroid concentrations in GnRH antagonist protocol: A sub-analysis of Ganirelix phase III study of China.J Gynecol Obstet Hum Reprod | PMID 35318120无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.Clin Lung Cancer | PMID 35331641无 PMCID | 2022-May | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.Lancet Diabetes Endocrinol | PMID 35378069PMC10851108 | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Blood Component Requirements and Erythrocyte Transfusion and Mortality Related to Hemoglobin Deficit in Phase III Trial of Hemoglobin-Based Oxygen Carrier: HBOC-201.Am J Ther | PMID 35421008无 PMCID | 2022 May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.Lancet Oncol | PMID 35427469无 PMCID | 2022-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.Lancet Oncol | PMID 35427471PMC9533375 | 2022-May | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.Lancet Neurol | PMID 35429480无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of low-molecular-weight heparin in the treatment of moderately severe and severe acute pancreatitis; a randomized, single blind, phase 3 control trial.Int J Surg | PMID 35489648无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.Mult Scler Relat Disord | PMID 35537314无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.Nat Med | PMID 35551292PMC9117147 | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.Nat Med | PMID 35551294无 PMCID | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.RMD Open | PMID 35577477PMC9114845 | 2022-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.Lancet | PMID 35367007无 PMCID | 2022-Apr-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.Lancet | PMID 35405085无 PMCID | 2022-Apr-30 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet | PMID 35427481无 PMCID | 2022-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.Brain | PMID 35038723PMC9050528 | 2022-Apr-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prevalence of polypharmacy in community-dwelling older adults from seven centres in five European countries: a cross-sectional study of DO-HEALTH.BMJ Open | PMID 35487733PMC9058693 | 2022-Apr-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Does experiencing a traumatic life event increase the risk of intimate partner violence for young women? A cross-sectional analysis and structural equation model of data from the Stepping Stones and Creating Futures intervention in South Africa.BMJ Open | PMID 35487735PMC9058688 | 2022-Apr-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term effect of additional rehabilitation following botulinum toxin-A on upper limb activity in chronic stroke: the InTENSE randomised trial.BMC Neurol | PMID 35468766PMC9036685 | 2022-Apr-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.Lancet | PMID 35461558无 PMCID | 2022-Apr-23 | 1.00 | The study is a randomized Phase III oncology trial with time-to-event endpoints, but the intervention is surgical (segmentectomy vs. lobectomy) and does not contain a drug intervention. | 待处理 |
| Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.N Engl J Med | PMID 35443108无 PMCID | 2022-Apr-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.J Clin Oncol | PMID 35108059PMC9015199 | 2022-Apr-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study.Vaccine | PMID 35315323无 PMCID | 2022-Apr-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI.J Am Coll Cardiol | PMID 35422242无 PMCID | 2022-Apr-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.BMJ | PMID 35440464PMC9016493 | 2022-Apr-19 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.Clin Cancer Res | PMID 35121623PMC10234145 | 2022-Apr-14 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.Clin Cancer Res | PMID 35176136PMC9093780 | 2022-Apr-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |